1.Synergistic effect of Chinese materia medica and chemotherapeutic agents.
Wei ZHANG ; Xiao-ping QIAN ; Bao-rui LIU
Chinese Journal of Integrated Traditional and Western Medicine 2007;27(10):952-956
Both in vitro and in vitro studies have proved that partial of Chinese materia medica including monomer or active ingredients have synergistic action with chemotherapeutic agents, the former could enhance the effect of the latter. Its mechanism may be correlated with the actions of Chinese materia medica in enhancing immune function, directly killing tumor cells, inducing tumor cell apoptosis, regulating cell cycle and reversing chemotherapeutic drug resistance, etc. The present article summarized the synergistic effect of Chinese materia medica, monomer or active ingredients, with various chemotherapeutic agents, and tried to provide a theoretical evidence for combined application of them in the procedure of clinical tumor treatment.
Antineoplastic Agents
;
therapeutic use
;
Antineoplastic Agents, Phytogenic
;
therapeutic use
;
Drug Synergism
;
Drug Therapy, Combination
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Integrative Medicine
;
methods
3.Efficacy of chemotherapy using 10-hydroxycamptothecin on recurrent or refractory neuroblastoma in children.
Zhe-Feng YUAN ; Yong-Min TANG ; Hua SONG ; Shu-Wen SHI ; Shi-Long YANG ; Bin-Hua PAN ; Fen-Ying ZHAO
Chinese Journal of Contemporary Pediatrics 2009;11(5):361-363
OBJECTIVEThe patients with recurrent or refractory neuroblastoma have a very poor prognosis and high mortality. 10-hydroxycamptothecin (HCPT) is a new agent extracted from comptotheca acuminate, a native plant. It has been shown to be very effective in some solid tumors such as gastric and colon cancers, lung cancers and ovary cancers. However, its efficacy in neuroblastoma has not been determined. This study aimed to investigate the therapeutic effects of HCPT in the treatment of recurrent or refractory neuroblastoma in children.
METHODSTen children with recurrent neuroblastoma and two children with refractory neuroblastoma were treated with HCPT. Of them, 5 children with recurrent neuroblastoma were treated with HCPT alone, and the other 7 patients received combination chemotherapy of HCPT plus other agents. The HCPT alone treatment group was injected with HCPT (7.5 mg/m2 daily) for 14 consecutive days. The combination chemotherapy group was alternately treated with the modified new protocol A1 (cyclophosomide 1 200 mg/m2 on day 1, etoposide 100 mg/m2 on days 1-5, HCPT 5 mg/m2 on days 1-3, cisplatin 90 mg/m2 on day 4) and the modified protocol B (ifosfomide 1.5 g/m2 on days 1-5, HCPT 5 mg/m2 on days 1-3, carboplatin 450 mg/m2 on day 2).
RESULTSFour patients (33.3%) achieved partial remission and 8 patients (66.7%) had stable disease. The median remission duration was 3.5 months (2-5 months). HCPT treatment as a single agent resulted in mild side effects. Myelosuppression and digestive disorders were found as the main adverse events in the combined chemotherapy group. No chemotherapy related deaths were found.
CONCLUSIONSHCPT is safe and effective in the treatment of recurrent or refractory neuroblastoma. The toxicities of HCPT are tolerable. The long-term efficacy of HCPT warrants further research.
Adolescent ; Antineoplastic Agents, Phytogenic ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Camptothecin ; analogs & derivatives ; therapeutic use ; Child ; Child, Preschool ; Female ; Humans ; Male ; Neuroblastoma ; drug therapy ; Recurrence
4.Anticancer effects of Chinese herbal medicine, science or myth?
Wen-jing RUAN ; Mao-de LAI ; Jian-guang ZHOU
Journal of Zhejiang University. Science. B 2006;7(12):1006-1014
Currently there is considerable interest among oncologists to find anticancer drugs in Chinese herbal medicine (CHM). In the past, clinical data showed that some herbs possessed anticancer properties, but western scientists have doubted the scientific validity of CHM due to the lack of scientific evidence from their perspective. Recently there have been encouraging results, from a western perspective, in the cancer research field regarding the anticancer effects of CHM. Experiments showed that CHM played its anticancer role by inducing apoptosis and differentiation, enhancing the immune system, inhibiting angiogenesis, reversing multidrug resistance (MDR), etc. Clinical trials demonstrated that CHM could improve survival, increase tumor response, improve quality of life, or reduce chemotherapy toxicity, although much remained to be determined regarding the objective effects of CHM in human in the context of clinical trials. Interestingly, both laboratory experiments and clinical trials have demonstrated that when combined with chemotherapy, CHM could raise the efficacy level and lower toxic reactions. These facts raised the feasibility of the combination of herbal medicines and chemotherapy, although much remained to be investigated in this area.
Antineoplastic Agents, Phytogenic
;
pharmacology
;
therapeutic use
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Clinical Trials as Topic
;
Drugs, Chinese Herbal
;
pharmacology
;
therapeutic use
;
Humans
5.Lobelia chinensis: chemical constituents and anticancer activity perspective.
Mei-Wan CHEN ; Wen-Rong CHEN ; Jin-Ming ZHANG ; Xiao-Ying LONG ; Yi-Tao WANG
Chinese Journal of Natural Medicines (English Ed.) 2014;12(2):103-107
Research has demonstrated that many chemical constituents dominated by piperidine alkaloids and flavonoids, such as lobelanidine, lobeline, and lobelanine, have been obtained from Lobelia chinensis Lour. Experimental studies and clinical applications have also indicated that L. chinensis possesses a number of pharmacological activities (e.g., diuretic, choleretic, breathing excitement, anti-venom, anti-bacterial, and anticancer). This paper focuses on the properties, chemical constituents, and anticancer activity of L. chinensis to clarify the connection among them, and identify the active anticancer compounds. This work serves as the foundation for further research and development of L. chinensis.
Alkaloids
;
pharmacology
;
therapeutic use
;
Animals
;
Antineoplastic Agents, Phytogenic
;
pharmacology
;
therapeutic use
;
Flavonoids
;
pharmacology
;
therapeutic use
;
Humans
;
Lobelia
;
chemistry
;
Neoplasms
;
drug therapy
;
Phytotherapy
;
Plant Extracts
;
pharmacology
;
therapeutic use
7.Research progress on effect of coumarins compounds in anti-tumor.
Guang HAO ; Zhen-Guo WANG ; Wen-Yan FU ; Ying YANG
China Journal of Chinese Materia Medica 2008;33(18):2016-2019
Coumarins are a group of important natural compounds, and have been found to have multi-biological activities such as anti-HIV, anti-tumor, anti-hypertension, anti-arrhythmia, anti-osteoporosis, assuaging pain, preventing asthma and antisepsis. One of which is its anti-tumor effect and that is a research focus on. Therefore, we believe that it is necessaryto carry out further studies on the effect of coumarins compounds in anti-tumor. Investigation should emphasize on improving techniques for extraction and separation, searching the effective precursory compound, and synthesizing and screening out courmarin derivatives with high activity and low toxicity. Here the recent research progress in anti-tumor effect of coumarins compounds is reviewed.
Anti-Arrhythmia Agents
;
pharmacology
;
therapeutic use
;
Anti-HIV Agents
;
pharmacology
;
therapeutic use
;
Antihypertensive Agents
;
pharmacology
;
therapeutic use
;
Antineoplastic Agents, Phytogenic
;
pharmacology
;
therapeutic use
;
Coumarins
;
pharmacology
;
therapeutic use
;
Humans
;
Neoplasms
;
drug therapy
8.Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Chao ZENG ; Hang ZHOU ; Yang WEI ; Liyang WANG ; Hua XIE ; Wenxiu YAO
Chinese Medical Journal 2014;127(5):951-956
BACKGROUNDStudies have shown that irinotecan can improve survival in patients with advanced or recurrent gastric cancer, but the overall benefit of irinotecan in the treatment of advanced or recurrent gastric cancer remains controversial. The aim of this study was to evaluate the benefits and risks of irinotecan for survival in patients with advanced or recurrent gastric cancer. Method We searched PubMed, EmBase, the Cochrane Central Register of Controlled Trials, reference lists of articles, and proceedings of major conferences for relevant clinical trials. We included randomized controlled trials that reported on the efficacy and safety of irinotecan in patients with advanced or recurrent gastric cancer. Outcomes were analyzed by survival rate, objective response rate (ORR), and toxicity. Furthermore, the analysis was further stratified by factors that could affect the treatment effects.
RESULTSEight trials recruiting 1 546 patients with advanced or recurrent gastric cancer were included in the analysis. Overall, irinotecan therapy was associated with a 6% improvement in survival rate, but this difference was not statistically significant (odds ratio (OR) 0.94; 95% confidence interval (95% CI) 0.70-1.27; P = 0.69). However, irinotecan therapy had more frequent ORR than irinotecan-free arm (OR 1.70; 95% CI 1.34-2.17; P < 0.001). Furthermore, irinotecan therapy was associated with a clinically and statistically significant increase in the risk for declined hemoglobin, hyponatremia, and diarrhea, but it also protected against thrombocytopenia risk when compared with irinotecan-free therapy.
CONCLUSIONSThere is no evidence to support the use of irinotecan therapy in patients with advanced or recurrent gastric cancer; however, given the significant advantage in ORR irinotecan therapy using combination regimens may be considered for further evaluation in subsets of patients who may benefit from this treatment.
Antineoplastic Agents, Phytogenic ; therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Camptothecin ; analogs & derivatives ; therapeutic use ; Humans ; Neoplasm Recurrence, Local ; drug therapy ; Stomach Neoplasms ; drug therapy ; Treatment Outcome
9.Modulation of signal transduction pathways by natural compounds in cancer.
Alok RANJAN ; Neel M FOFARIA ; Sung-Hoon KIM ; Sanjay K SRIVASTAVA
Chinese Journal of Natural Medicines (English Ed.) 2015;13(10):730-742
Cancer is generally regarded as the result of abnormal growth of cells. According to World Health Organization, cancer is the leading cause of mortality worldwide. Mother nature provides a large source of bioactive compounds with excellent therapeutic efficacy. Numerous phytochemicals from nature have been investigated for anticancer properties. In this review article, we discuss several natural compounds, which have shown anti-cancer activity. Natural compounds induce cell cycle arrest, activate intrinsic and extrinsic apoptosis pathways, generate Reactive Oxygen Species (ROS), and down-regulate activated signaling pathways, resulting in inhibition of cell proliferation, progression and metastasis of cancer. Several preclinical studies have suggested that natural compounds can also increase the sensitivity of resistant cancers to available chemotherapy agents. Furthermore, combining FDA approved anti-cancer drugs with natural compounds results in improved efficacy. On the basis of these exciting outcomes of natural compounds against several cancer types, several agents have already advanced to clinical trials. In conclusion, preclinical results and clinical outcomes against cancer suggest promising anticancer efficacy of agents from natural sources.
Animals
;
Antineoplastic Agents, Phytogenic
;
pharmacology
;
therapeutic use
;
Humans
;
Magnoliopsida
;
chemistry
;
Neoplasms
;
drug therapy
;
Phytochemicals
;
pharmacology
;
therapeutic use
;
Phytotherapy
;
Plant Extracts
;
pharmacology
;
therapeutic use
;
Signal Transduction
;
drug effects
10.Biocompatible and biodegradable nanoparticles for enhancement of anti-cancer activities of phytochemicals.
Chuan LI ; Jia ZHANG ; Yu-Jiao ZU ; Shu-Fang NIE ; Jun CAO ; Qian WANG ; Shao-Ping NIE ; Ze-Yuan DENG ; Ming-Yong XIE ; Shu WANG
Chinese Journal of Natural Medicines (English Ed.) 2015;13(9):641-652
Many phytochemicals show promise in cancer prevention and treatment, but their low aqueous solubility, poor stability, unfavorable bioavailability, and low target specificity make administering them at therapeutic doses unrealistic. This is particularly true for (-)-epigallocatechin gallate, curcumin, quercetin, resveratrol, and genistein. There is an increasing interest in developing novel delivery strategies for these natural products. Liposomes, micelles, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers and poly (lactide-co-glycolide) nanoparticles are biocompatible and biodegradable nanoparticles. Those nanoparticles can increase the stability and solubility of phytochemicals, exhibit a sustained release property, enhance their absorption and bioavailability, protect them from premature enzymatic degradation or metabolism, prolong their circulation time, improve their target specificity to cancer cells or tumors via passive or targeted delivery, lower toxicity or side-effects to normal cells or tissues through preventing them from prematurely interacting with the biological environment, and enhance anti-cancer activities. Nanotechnology opens a door for developing phytochemical-loaded nanoparticles for prevention and treatment of cancer.
Antineoplastic Agents, Phytogenic
;
administration & dosage
;
therapeutic use
;
Drug Carriers
;
Humans
;
Materials Testing
;
Nanoparticles
;
Neoplasms
;
drug therapy
;
Phytochemicals
;
administration & dosage
;
therapeutic use
;
Plant Extracts
;
administration & dosage
;
therapeutic use